FDA Inspection
Haematologic Technologies, LLC dba ProlytixHaematologic Technologies, LLC dba Prolytix – FDA Inspection, May 11, 2017
Record Details
This FDA Inspection record concerns Haematologic Technologies, LLC dba Prolytix, with an inspection on May 11, 2017, issued by the Center for Drug Evaluation and Research, covering drugs.
View Company Profile
ID · c6e6dd3e-5093-458a-9a69-6b09b1f005a4
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1013147
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
- Outcome
- Form 483 issued
FDA Citations
1- 21 CFR 211.194(a)(8)Identification of Person Performing Review of Lab Records
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Haematologic Technologies, LLC dba Prolytix
6| Date | Classification | Office | Project area |
|---|---|---|---|
| April 17, 2026 | Not classified | New England District Office | |
| January 6, 2025 | Not classified | New England District Office | |
| July 30, 2021 | VAI | Center for Biologics Evaluation and Research | Blood and Blood Products |
| June 27, 2019 | VAI | Center for Biologics Evaluation and Research | Blood and Blood Products |
| July 28, 2017 | NAI | Center for Biologics Evaluation and Research | Blood and Blood Products |
Other documents for Haematologic Technologies, LLC dba Prolytix
- FDA Inspection 1314930 - 2026-04-17
- FDA Inspection 1258523 - 2025-01-06
- FDA Inspection 1147450 - 2021-07-30
- FDA Inspection 1098078 - 2019-06-27
- FDA Inspection 1027695 - 2017-07-28
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.